AM-411 / Altamira Therap - LARVOL DELTA

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation (GlobeNewswire) - "Altamira Therapeutics...today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the Company’s OligoPhore platform and siRNA targeting the p65 protein, a component of the NF-κB transcription factor....The new filing is intended to extend Altamira’s intellectual property related to its AM-411 development program for RA treatment, among others."

Patent • Rheumatoid Arthritis

Altamira Therapeutics Provides Investor and Business Update (GlobeNewswire) - "Meanwhile, Altamira is also pursuing the partnering of its other legacy assets, which include several development programs in inner ear therapeutics. Discussions are most advanced regarding AM-125, a nasal spray for the treatment of acute vestibular syndrome, a very frequent type of dizziness. Altamira invested more than $18 million to date and demonstrated proof of concept in a Phase 2 trial. There is no comparable product in the US. The Company expects significant partnering progress during the first half of 2024....The Company has an expanding pipeline of business development projects with potential collaboration partners and expects important progress in 2024. Altamira’s two flagship programs, AM-401 and AM-411, for KRAS-driven cancer and rheumatoid arthritis respectively, serve to demonstrate the technology’s potential and shall be licensed out following the IND (expected for early 2025) or after a Phase 1 trial, at the latest."

Commercial • Financing • IND • CNS Disorders • Immunology • Inflammation • Rheumatoid Arthritis • Vertigo